Cargando…

Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells

Background: Ovaries are sensitive to chemotherapy, which may lead to early depletion of primordial follicle reserve. One strategy for gonadal function preservation is temporary ovarian suppression with Gonadotropin Releasing Hormone agonists (GnRHa) during chemotherapy. To date, GnRHa protective mec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scaruffi, Paola, Stigliani, Sara, Cardinali, Barbara, Massarotti, Claudia, Lambertini, Matteo, Sozzi, Fausta, Dellepiane, Chiara, Merlo, Domenico Franco, Anserini, Paola, Del Mastro, Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928931/ https://www.ncbi.nlm.nih.gov/pubmed/31801245 http://dx.doi.org/10.3390/ijms20236045

Ejemplares similares

Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy
por: Massarotti, C., et al.
Publicado: (2023)

Fifteen Year Regional Center Experience in Sperm Banking for Cancer Patients: Use and Reproductive Outcomes in Survivors
por: Stigliani, Sara, et al.
Publicado: (2021)

Pronuclear score improves prediction of embryo implantation success in ICSI cycles
por: Stigliani, Sara, et al.
Publicado: (2021)

Oral Antioxidant Treatment of Men Significantly Improves the Reproductive Outcome of IVF Cycles
por: Scaruffi, Paola, et al.
Publicado: (2021)

Semen parameters and male reproductive potential are not adversely affected after three or more months of recovery from COVID-19 disease
por: Stigliani, Sara, et al.
Publicado: (2023)

Re: Safety and efficacy concerns of long-acting GnRH agonist trigger for ovulation induction in oncological patients undergoing oocyte cryopreservation: a call for caution and further investigation
por: Massarotti, C., et al.
Publicado: (2023)

Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review
por: Poggio, Francesca, et al.
Publicado: (2019)

mRNA and Viral Vector COVID-19 Vaccines Do Not Affect Male Fertility: A Prospective Study
por: Massarotti, Claudia, et al.
Publicado: (2022)

Does SARS-CoV-2 Affect the Prostate? A Molecular Analysis from a Case Series of COVID-19 Patients
por: Stigliani, Sara, et al.
Publicado: (2023)

Effect of Multiple Sclerosis and Its Treatments on Male Fertility: Cues for Future Research
por: Massarotti, Claudia, et al.
Publicado: (2021)

Contraception and Hormone Replacement Therapy in Healthy Carriers of Germline BRCA1/2 Genes Pathogenic Variants: Results from an Italian Survey
por: Massarotti, Claudia, et al.
Publicado: (2022)

Gonadotropin releasing hormone agonists: Expanding vistas
por: Magon, Navneet
Publicado: (2011)

The Role of Cyclin-Dependent Kinases (CDK) 4/6 in the Ovarian Tissue and the Possible Effects of Their Exogenous Inhibition
por: Scavone, Graziana, et al.
Publicado: (2023)

Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis
por: Bonardi, Benedetta, et al.
Publicado: (2020)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
por: Keane, Fergus, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
por: Shiasi Arani, Kobra, et al.
Publicado: (2015)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?
por: Lambertini, Matteo, et al.
Publicado: (2019)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

The role of gonadotropin-releasing hormone agonists in female fertility preservation
por: Lee, Jae Hoon, et al.
Publicado: (2021)

Dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves oocyte yield in normal responders on GnRH-antagonist cycles
por: Albeitawi, Soha, et al.
Publicado: (2022)

Comparative Gene Expression Profiling in Human Cumulus Cells according to Ovarian Gonadotropin Treatments
por: Assou, Said, et al.
Publicado: (2013)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
por: Zhou, Feng, et al.
Publicado: (2016)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?
por: Yilmaz, Nafiye, et al.
Publicado: (2019)

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer
por: Mastandrea, Katherine, et al.
Publicado: (2023)

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles
por: Tehraninejad, Ensieh Sh., et al.
Publicado: (2010)

Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger)
por: de Oliveira, Sofia Andrade, et al.
Publicado: (2016)

Effects of gonadotropin-releasing hormone agonist on human chorionic gonadotropin activity in granulosa cells of immature female rats
por: TUNGMAHASUK, Doungrut, et al.
Publicado: (2017)

Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves the outcome of intrauterine insemination
por: Halim, Binarwan, et al.
Publicado: (2022)

The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer
por: Blondeaux, Eva, et al.
Publicado: (2021)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Apoptotic Death of Prostate Cancer Cells by a Gonadotropin-Releasing Hormone-II Antagonist
por: Park, Sumi, et al.
Publicado: (2014)

Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
por: Choi, Seungtaek, et al.
Publicado: (2011)

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
por: Han, Eun Jin, et al.
Publicado: (2013)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients
por: Lambertini, Matteo, et al.
Publicado: (2017)

Clinical efficacy of dual trigger with human chorionic gonadotropin and a gonadotropin‐releasing hormone agonist for women undergoing fertility preservation
por: Hong, Yeon Hee, et al.
Publicado: (2022)

Anti-Müllerian Hormone Inhibits FSH-Induced Cumulus Oocyte Complex In Vitro Maturation and Cumulus Expansion in Mice
por: Yu, Xue, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_et79fclu6lo3j1b1cfkvgkhedg